Enuresis
Involuntary discharge of URINE after expected age of completed development of urinary control. This can happen during the daytime (DIURNAL ENURESIS) while one is awake or during sleep (NOCTURNAL ENURESIS). Enuresis can be in children or in adults (as persistent primary enuresis and secondary adult-onset enuresis).
Subtype terms (2)
More specific conditions that are subtypes of Enuresis in the MeSH hierarchy.
- Diurnal Enuresis
3 drugs (1 approved, 2 experimental)
- Nocturnal Enuresis
11 drugs (6 approved, 5 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 2 trials (2)
Phase 1 trials (1)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (36)
- Astellas
- Eli Lilly
- Pfizer
- Allergan
- Boehringer Ingelheim
- Steba Biotech S.A.
- National Institute on Aging (NIA)
- Aarhus University
- University of Pittsburgh
- Cairo University
- University of London
- Harvard University
- Georgetown University
- Korea University
- Lund University
- Mansoura University
- McGill University
- Northwestern University
- Stanford University
- University of Louisville
- University of Ottawa
- University of South Florida
- University of Alberta
- Tel Aviv University
- Zhengzhou University
- University of California, San Francisco
- University of Ankara
- TriHealth
- University of Angers
- University of Sherbrooke
- +6 more
Organization Involved with Phase 3 Indications (30)
- Merck
- Alza
- Ipsen
- APOGEPHA Arzneimittel GmbH
- Antares Pharma Inc.
- GlaxoSmithKline
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Pennsylvania
- Ain Shams University
- Brown University
- Duke University
- Hormozgan University of Medical Sciences
- Kaiser Permanente
- Loyola University
- Nagoya University
- RTI International
- University of Toronto
- Mayo Clinic
- Far Eastern Memorial Hospital
- University of California, San Diego
- Vanderbilt University
- Hebrew University
- University of North Carolina at Chapel Hill
- University of Alabama, Birmingham
- National Institute of Child Health and Human Development (NICHD)
- Cook Medical
- IQVIA
- The University of Texas, Dallas
- Pelvic Floor Disorders Network
Organization Involved with Phase 2 Indications (27)
- McNeil
- Sanofi
- American Oriental Bioengineering, Inc.
- Beech Tree Labs, Inc.
- FemmePharma Global Healthcare, Inc.
- GTx
- Duramed Research
- Otsuka
- National Cancer Center, Japan
- United States Army
- China Academy of Chinese Medical Sciences
- Oakland University
- Universidad Autonoma de Madrid
- Wake Forest University
- University of Cologne
- University of Copenhagen
- Belarusian State Medical University
- UroGen Pharma
- Al Azhar University
- University of Texas, Galveston
- Norwich Clinical Research Associates Ltd.
- Johnson and Johnson
- People's Liberation Army of China
- Urovant Sciences Ltd.
- Ixaltis SA
- National Academy of Sciences of Belarus
- The state institution N. N. Alexandrov National Cancer Centre of Belarus
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (19)
- National Center for Complementary and Integrative Health (NCCIH)
- New England Research Institutes
- Shinshu University
- Silesian University of Medicine
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- University of New Mexico
- University of Rochester
- University of Science Malaysia
- University of Virginia
- Fudan University
- University of California, Irvine
- University of Queensland
- Charles Drew University
- Vita-Salute University of Milano. Italy
- Department of Veteran Affairs
- University of Tasmania
- Seipel Group Pty Ltd
- Endeavour College of Natural Health
- Imam Abdulrahman Bin Faisal University